REGN vs. V
Compare and contrast key facts about Regeneron Pharmaceuticals, Inc. (REGN) and Visa Inc. (V).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: REGN or V.
Correlation
The correlation between REGN and V is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
REGN vs. V - Performance Comparison
Loading data...
Key characteristics
REGN:
-1.21
V:
1.45
REGN:
-1.80
V:
2.01
REGN:
0.78
V:
1.30
REGN:
-0.71
V:
2.18
REGN:
-1.22
V:
7.28
REGN:
32.36%
V:
4.48%
REGN:
32.05%
V:
21.88%
REGN:
-91.81%
V:
-51.90%
REGN:
-50.48%
V:
0.00%
Fundamentals
REGN:
$63.16B
V:
$682.86B
REGN:
$39.37
V:
$10.11
REGN:
14.86
V:
35.84
REGN:
1.26
V:
2.38
REGN:
4.48
V:
18.15
REGN:
2.15
V:
18.68
REGN:
$14.09B
V:
$37.62B
REGN:
$11.96B
V:
$30.13B
REGN:
$4.98B
V:
$25.84B
Returns By Period
In the year-to-date period, REGN achieves a -16.46% return, which is significantly lower than V's 15.92% return. Over the past 10 years, REGN has underperformed V with an annualized return of 1.68%, while V has yielded a comparatively higher 18.81% annualized return.
REGN
-16.46%
8.20%
-21.37%
-38.52%
0.63%
1.68%
V
15.92%
10.38%
18.31%
31.43%
15.61%
18.81%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
REGN vs. V — Risk-Adjusted Performance Rank
REGN
V
REGN vs. V - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Visa Inc. (V). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
REGN vs. V - Dividend Comparison
REGN's dividend yield for the trailing twelve months is around 0.15%, less than V's 0.63% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
V Visa Inc. | 0.63% | 0.68% | 0.72% | 0.76% | 0.62% | 0.56% | 0.56% | 0.67% | 0.61% | 0.75% | 0.64% | 0.64% |
Drawdowns
REGN vs. V - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than V's maximum drawdown of -51.90%. Use the drawdown chart below to compare losses from any high point for REGN and V. For additional features, visit the drawdowns tool.
Loading data...
Volatility
REGN vs. V - Volatility Comparison
Regeneron Pharmaceuticals, Inc. (REGN) has a higher volatility of 17.04% compared to Visa Inc. (V) at 5.47%. This indicates that REGN's price experiences larger fluctuations and is considered to be riskier than V based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
REGN vs. V - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Visa Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REGN vs. V - Profitability Comparison
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.56B and revenue of 3.03B. Therefore, the gross margin over that period was 84.7%.
V - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Visa Inc. reported a gross profit of 7.71B and revenue of 9.59B. Therefore, the gross margin over that period was 80.4%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported an operating income of 591.70M and revenue of 3.03B, resulting in an operating margin of 19.5%.
V - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Visa Inc. reported an operating income of 5.44B and revenue of 9.59B, resulting in an operating margin of 56.7%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a net income of 808.70M and revenue of 3.03B, resulting in a net margin of 26.7%.
V - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Visa Inc. reported a net income of 4.58B and revenue of 9.59B, resulting in a net margin of 47.7%.